Corpus Intelligence IC Memo — LIFEBRITE COMM HOSP OF STOKES 2026-04-26 12:49 UTC
IC Memo — LIFEBRITE COMM HOSP OF STOKES
Investment Committee Memorandum | NC | 25 beds | Grade C | EBITDA uplift $1.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LIFEBRITE COMM HOSP OF STOKES

CCN 341317 | nan, NC | 25 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

LIFEBRITE COMM HOSP OF STOKES is a 25-bed rural/critical access in nan, NC with $14.2M in net patient revenue and a 5.3% operating margin. The hospital serves a payer mix of 39.2% Medicare, 0.3% Medicaid, and 60.5% commercial.

Thesis: Turnaround. Our ML models identify $1.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.3% to 12.6% (+737bps).

Net Revenue HCRIS$14.2M
Current EBITDA COMPUTED$746K
Operating Margin COMPUTED5.3%
Occupancy HCRIS15.7%
Revenue / Bed COMPUTED$566K
Net-to-Gross HCRIS42.7%
Distress Probability ML57.7%

2. Market Context & Competitive Position

129
NC Hospitals
-2.0%
State Median Margin
38
Comparable Hospitals

NC has 129 Medicare-certified hospitals with a median operating margin of -2.0%. The target's margin of 5.3% places it above the state median. Among 38 size-comparable peers (12-50 beds), the median margin is -5.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 38 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LIFEBRITE COMM HOSP OF STOKES (Target)NC25$14.2M5.3%
DAVIE MEDICAL CENTERNC42$108.5M27.5%
NOVANT HEALTH MINT HILL MEDICANC36$107.8M9.7%
THE OUTER BANKS HOSPITALNC21$93.7M26.2%
MEDICAL PARK HOSPITALNC22$82.6M15.8%
GRANVILLE MEDICAL CENTERNC42$81.5M-5.4%
NORTH CAROLINA SPECIALTY HOSPINC18$71.6M11.7%
CAPE FEAR VALLEY HOKE HOSPITALNC41$71.5M19.3%
THE MCDOWELL HOSPITALNC30$65.7M-6.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.0M (737bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$297K+210bp18mo
Cost to Collect4.5%2.5%$283K+200bp12mo
Denial Rate Reduction12.0%6.5%$281K+198bp12mo
A/R Days Reduction5200.0%3800.0%$172K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+7bp6mo

5. EBITDA Bridge

Net Collection Rate
$297K
Cost to Collect
$283K
Denial Rate Reduction
$281K
A/R Days Reduction
$172K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.0M
Current EBITDA$746K
+ RCM Uplift+$1.0M
Pro Forma EBITDA$1.8M
Current Margin5.3%
Pro Forma Margin12.6%
WC Released (1x)$543K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.1M$15.3M13.38x68.0%
Base (11x exit)10.0x11.0x$1.1M$17.3M15.04x72.0%
Bull Case9.0x11.0x$1.0M$21.1M20.41x82.8%
Bull (12x exit)9.0x12.0x$1.0M$23.3M22.56x86.5%
Bear Case11.0x10.0x$1.3M$9.8M7.74x50.6%
Bear (11x exit)11.0x11.0x$1.3M$11.1M8.83x54.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 15.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 57.7% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 38 hospitals with 12-50 beds
  • Same-state prioritization (n=39)
  • Comp margins: P25=-22.6% / P50=-5.4% / P75=4.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.